BillionToOne, Inc. (BLLN) is a Menlo Park, California–based molecular diagnostics company whose single-molecule counting platform powers UNITY prenatal screening and the Northstar liquid biopsy franchise for oncology. Its shares traded at $89.66 shortly after 10 a.m. ET on Wednesday, a decline of 8.04% from Tuesday's closing price of $97.50. The direction is clearly negative, and the move is idiosyncratic rather than sector-driven: a critical short-seller report published before the open alleged improper billing, undisclosed state-level scrutiny and weaker clinical differentiation than management claims.
Fuzzy Panda Research disclosed a short position in BLLN and published a report built on state public-records requests, interviews with anonymous former employees and conversations with physicians. The most consequential allegation concerns Tennessee Medicaid: the report says state records show an integrity inquiry opened in 2024 after 11 tips and was referred to the Tennessee Bureau of Investigation's Medicaid fraud unit, and that billing records reflect the use of unlisted CPT codes reimbursed at roughly ten times standard rates. It also questions why that scrutiny never appeared in the company's securities filings.
A second thread examines Michigan Medicaid data, claiming the company billed once-in-a-lifetime genetic carrier screening alongside about 88% of its non-invasive prenatal tests — well above the roughly 40% of pregnancies involving first-time mothers — and that sales staff capped patient deductibles and copays between $99 and $349 without income verification. BillionToOne has not publicly responded, and a referral to a law enforcement agency does not establish wrongdoing; no charges or regulatory findings exist.
The report's financial framing matters more than the individual anecdotes for a company valued near $4.3 billion. Fuzzy Panda estimated that curbing carrier-screening claims it deems excessive could erase about 80% of EBITDA, and modeled hypothetical False Claims Act exposure above $1.2 billion — its own estimate, not a booked liability. The report also flags rising days sales outstanding and insurer disputes, and cites oncologists skeptical of Northstar's differentiation, on top of alleged undisclosed prenatal false negatives.
That lands on an already fragile narrative. Third-quarter revenue of $123 million, up 47% year over year, and raised 2026 guidance of $460 million to $470 million were well received on Nov. 4, yet the stock still sold off as investors fixated on the timing of Medicare coverage for Northstar Response, PAMA reimbursement changes and the durability of true-up revenue. Wednesday's report simply gave that caution a sharper edge and forced a repricing of revenue quality rather than growth.
Turnover was heavy, with roughly 154,000 shares changing hands in the first half hour — a pace well ahead of the stock's typical daily volume. The move diverged sharply from the tape: the health care sector ETF slipped about 0.85% and the Nasdaq-100 rose 0.7%, while diagnostics peers were mixed, with NTRA down 1.33%, GH and TEM roughly flat and MYGN up 1.44%. Technically, BLLN had already lost its 50-day moving average near $104 and the $96 support area earlier this week; Wednesday's dip to $85.71 marked its lowest intraday print since mid-August, and the stock remains far below its 52-week high of $150.44.
The score runs from 0, meaning no meaningful news and an ordinary move for the stock, to 100, meaning transformative news and a rare, extreme price move. This event earns 50 out of 100.
A named short-seller report alleging billing irregularities, undisclosed investigative scrutiny and roughly 80% EBITDA risk is substantial relative to a $4.3 billion company, but the claims are unproven and no regulator has issued findings. The price reaction was meaningful but not historic: today's 8.04% decline is about 2.9 times the stock's average absolute daily move of 2.77% over the past 60 sessions, and moves of similar or greater size occurred five times in that span. A strong news component paired with a moderately unusual move produces the mid-range score.
The immediate focus is whether management issues a detailed rebuttal, since the allegations now sit alongside a reimbursement story that already concerned investors. Fourth-quarter and full-year 2026 results are expected in early March 2027, and the Dec. 15 commercial launch of Northstar Clear, a tissue-free minimal residual disease test, will be the next hard datapoint on the oncology franchise. Also in view: Medicare coverage timing for Northstar Response, PAMA-related reimbursement shifts, days-sales-outstanding trends, and any analyst revisions to revenue-quality assumptions. Risks cut both ways — a credible rebuttal could stabilize the shares, while regulatory escalation or insurer pushback would keep pressure on a stock still trading near triple-digit earnings multiples.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics and traded symbols, so the lineup shifts as conditions change. Reviewing the current leaders is a practical way to see how automated strategies are positioned right now — explore the page to find the bots best suited to your approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
BLLN saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator turned negative. In 19 of the 21 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for BLLN turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BLLN moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BLLN crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BLLN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for BLLN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 48 of 54 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
BLLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BLLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.016) is normal, around the industry mean (67.298). BLLN has a moderately high P/E Ratio (136.508) as compared to the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalSpecialties